<DOC>
	<DOCNO>NCT00003631</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill tumor cell . PURPOSE : Phase II trial study effectiveness chemotherapy plus radiation therapy treat patient refractory relapse Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Chemotherapy Plus Radiation Therapy Treating Patients With Refractory Relapsed Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Assess efficacy high-dose chemoradiotherapy regimen patient refractory relapsed Hodgkin 's lymphoma . OUTLINE : Patients stratify 1 3 treatment arm ( 0-1 adverse prognostic factor vs 2 adverse prognostic factor vs 3 adverse prognostic factor ) . - Arm I ( 0-1 adverse prognostic factor ) : Patients receive ifosfamide 24 hour infusion day 2 . Carboplatin administer day 2 . Etoposide IV administer daily day 1-3 . Patients receive filgrastim ( G-CSF ) subcutaneously IV day 5-12 . Patients receive another course ICE chemotherapy 2-3 week first course . Leukapheresis perform WBC reach least 3000/mm^3 continue enough peripheral blood stem cell collect . Patients never receive prior radiotherapy receive accelerate hyperfractionated total lymphoid irradiation ( TLI ) twice day 5 day ( day -10 -6 ) . Cyclophosphamide IV administer day -5 4 . Etoposide IV administer continuous infusion 4 day ( day -5 -2 ) . Patients prior radiotherapy receive high dose chemotherapy . Cyclophosphamide IV administer day -6 -5 . Etoposide IV administer continuous infusion 4 day ( day -6 -3 ) . Carmustine IV administer day -2 . Peripheral blood stem cell infuse 24-36 hour high-dose chemotherapy . G-CSF administer begin day 1 continue blood count recover . - Arm II ( 2 adverse prognostic factor ) : Patients receive first course ICE Arm I. Apheresis perform WBC great 3000/mm^3 continue enough cell collect . The second course ICE administer . Ifosfamide administer 48 hour continuous infusion day 1-2 . Carboplatin administer day 3 . Etoposide IV administer every 12 hour 3 dos begin day 1 . Patients receive G-CSF day 5-14 . Patients never receive prior radiotherapy receive accelerate hyperfractionated TLI 5 day ( day -10 -6 ) . Cyclophosphamide IV administer every 12 hour day -5 -2 . Etoposide IV administer continuous infusion 4 day ( day -5 -2 ) . Patients prior radiotherapy receive high-dose chemotherapy . Cyclophosphamide IV administer every 12 hour day -6 -3 . Etoposide IV administer continuous infusion 4 day ( day -6 -3 ) . Carmustine IV administer day -2 . Peripheral blood stem cell infuse 24-36 hour high dose chemotherapy . G-CSF administer begin day 1 continue blood count recover . - Arm III ( 3 adverse prognostic factor ) : Patients receive cyclophosphamide IV daily 2 day , G-CSF begin day 4 blood stem cell collect . Patients undergo apheresis enough cell collect . Patients receive high-dose chemotherapy . Ifosfamide IV administer 1 hour . Etoposide administer continuous infusion 12 hour . Carboplatin IV administer 1 hour . Etoposide administer continuous infusion 12 hour . Treatment repeat daily 5 day . Peripheral blood stem cell reinfused 24-36 hour last dose chemotherapy . G-CSF administer begin day 1 continue blood count recover . Patients never receive prior radiation receive accelerate hyperfractionated TLI twice daily 5 day . Patients receive second course high dose chemotherapy 45-90 day reinfusion cell . Etoposide IV cytarabine IV administer every 12 hour 4 day ( day -6 -3 ) . Melphalan IV administer day -2 . Patients receive prior radiation therapy receive second course high-dose chemotherapy . Carmustine IV administer day -7 . Etoposide IV cytarabine IV administer every 12 hour 4 day ( day -6 -3 ) . Melphalan IV administer day -2 . Peripheral blood stem cell reinfused 24-48 hour completion second course chemotherapy . G-CSF administer begin day 1 continue blood count recover . Patients follow every 3 month first 2 year , every 4 month year 3-5 , every 6 month thereafter . PROJECTED ACCRUAL : This study accrue 80 patient within 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm residual relapse Hodgkin 's lymphoma follow conventional dose standard chemotherapy Presence follow prognostic factor allow : B symptom ( fever , weight loss , night sweat ) Extranodal disease Complete remission less 1 year duration PATIENT CHARACTERISTICS : Age : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2.0 mg/dL unless history Gilbert 's disease No chronic active persistent hepatitis Renal : No history chronic renal insufficiency Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No myocardial infarction within past 6 month No unstable angina No significant cardiac arrhythmia chronic atrial fibrillation Ejection fraction least 50 % Pulmonary : DLCO least 50 % Other : No uncontrolled infection HIV negative At least 5 year since prior malignancy except : Curatively treat cutaneous basal cell carcinoma Carcinoma situ cervix Not pregnant nursing Fertile woman must use effective contraception PRIOR CONCURRENT THERAPY : Must fail conventional dose standard chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
</DOC>